Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia.

Schlenk RF, Döhner H.

Hematology Am Soc Hematol Educ Program. 2013;2013:324-30. doi: 10.1182/asheducation-2013.1.324. Review.

2.

Impact of genetic features on treatment decisions in AML.

Döhner H, Gaidzik VI.

Hematology Am Soc Hematol Educ Program. 2011;2011:36-42. doi: 10.1182/asheducation-2011.1.36. Review.

3.

Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice.

Abdel-Wahab O.

Hematology. 2012 Apr;17 Suppl 1:S39-42. doi: 10.1179/102453312X13336169155411.

PMID:
22507776
4.

IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Krönke J, Bullinger L, Späth D, Kayser S, Zucknick M, Götze K, Horst HA, Germing U, Döhner H, Döhner K.

J Clin Oncol. 2010 Aug 1;28(22):3636-43. doi: 10.1200/JCO.2010.28.3762. Epub 2010 Jun 21.

5.

Prognostic implications of gene mutations in acute myeloid leukemia with normal cytogenetics.

Gaidzik V, Döhner K.

Semin Oncol. 2008 Aug;35(4):346-55. doi: 10.1053/j.seminoncol.2008.04.005. Review.

PMID:
18692685
6.

Implication of the molecular characterization of acute myeloid leukemia.

Döhner H.

Hematology Am Soc Hematol Educ Program. 2007:412-9. Review.

7.

[Advances of study on prognostic factors of molecular biology in acute myeloid leukemia with normal cytogenetics].

Han TJ, Xu XP.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Aug;18(4):1063-8. Review. Chinese.

PMID:
20723330
8.

Integrating genomics into prognostic models for AML.

Sanchez M, Levine RL, Rampal R.

Semin Hematol. 2014 Oct;51(4):298-305. doi: 10.1053/j.seminhematol.2014.08.002. Epub 2014 Aug 12.

9.

Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.

Baldus CD, Bullinger L.

Semin Oncol. 2008 Aug;35(4):356-64. doi: 10.1053/j.seminoncol.2008.04.006. Review.

PMID:
18692686
10.

Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.

Pastore F, Dufour A, Benthaus T, Metzeler KH, Maharry KS, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, Kakadia PM, Unterhalt M, Feuring-Buske M, Buske C, Braess J, Sauerland MC, Heinecke A, Krug U, Berdel WE, Buechner T, Woermann B, Hiddemann W, Bohlander SK, Marcucci G, Spiekermann K, Bloomfield CD, Hoster E.

J Clin Oncol. 2014 May 20;32(15):1586-94. doi: 10.1200/JCO.2013.52.3480. Epub 2014 Apr 7.

11.

Prognostically important molecular markers in cytogenetically normal acute myeloid leukemia.

Lin TL, Smith BD.

Am J Med Sci. 2011 May;341(5):404-8. doi: 10.1097/MAJ.0b013e318201109d. Review.

12.

Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity.

Taskesen E, Bullinger L, Corbacioglu A, Sanders MA, Erpelinck CA, Wouters BJ, van der Poel-van de Luytgaarde SC, Damm F, Krauter J, Ganser A, Schlenk RF, Löwenberg B, Delwel R, Döhner H, Valk PJ, Döhner K.

Blood. 2011 Feb 24;117(8):2469-75. doi: 10.1182/blood-2010-09-307280. Epub 2010 Dec 21.

13.

Genetic mutations in acute myeloid leukemia that influence clinical decisions.

Chung SS.

Curr Opin Hematol. 2014 Mar;21(2):87-94. doi: 10.1097/MOH.0000000000000024. Review.

PMID:
24445361
14.

RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.

Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, Dufour A, Schneider F, Schneider S, Kakadia PM, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK.

Haematologica. 2012 Dec;97(12):1909-15. doi: 10.3324/haematol.2012.064667. Epub 2012 Jun 11.

15.

Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.

Dvorakova D, Racil Z, Jeziskova I, Palasek I, Protivankova M, Lengerova M, Razga F, Mayer J.

Am J Hematol. 2010 Dec;85(12):926-9. doi: 10.1002/ajh.21879.

16.

Molecular pathogenesis of acute myeloid leukemia: a diverse disease with new perspectives.

Thol F, Ganser A.

Front Med China. 2010 Dec;4(4):356-62. doi: 10.1007/s11684-010-0220-5. Epub 2010 Dec 1. Review.

PMID:
21125345
17.

Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia.

Thol F, Damm F, Wagner K, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Heit W, Kanz L, Schlimok G, Raghavachar A, Fiedler W, Kirchner H, Heil G, Heuser M, Krauter J, Ganser A.

Blood. 2010 Jul 29;116(4):614-6. doi: 10.1182/blood-2010-03-272146. Epub 2010 Apr 26.

18.

Are results of targeted gene sequencing ready to be used for clinical decision making for patients with acute myelogenous leukemia?

Rao AV, Smith BD.

Curr Hematol Malig Rep. 2013 Jun;8(2):149-55. doi: 10.1007/s11899-013-0161-6. Review.

19.

Molecular prognostic factors in cytogenetically normal acute myeloid leukemia.

Walker A, Marcucci G.

Expert Rev Hematol. 2012 Oct;5(5):547-58. doi: 10.1586/ehm.12.45. Review.

20.

Genomic tools in acute myeloid leukemia: From the bench to the bedside.

White BS, DiPersio JF.

Cancer. 2014 Apr 15;120(8):1134-44. doi: 10.1002/cncr.28552. Epub 2014 Jan 28. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk